dipyridamole and Cerebral Infarction studies

Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.

Cerebral Infarction: The formation of an area of NECROSIS in the CEREBRUM caused by an insufficiency of arterial or venous blood flow. Infarcts of the cerebrum are generally classified by hemisphere (i.e., left vs. right), lobe (e.g., frontal lobe infarction), arterial distribution (e.g., INFARCTION, ANTERIOR CEREBRAL ARTERY), and etiology (e.g., embolic infarction).

Research Excerpts

Excerpt	Relevance	Reference
"Japanese guidelines recommend aspirin 160-300 mg/day, starting within 48 h, for patients with acute cerebral infarction."	7.80	Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan. ( Inuyama, L; Mizuno, O; Sakaguchi, T; Takahashi, S; Yamada, T, 2014)
" As for intracranial hemorrhage (ICH), stroke recurrence, and adverse event (AE) rate, there were no significant differences of efficacy among 7 drug therapies."	6.58	Aspirin plus dipyridamole has the highest surface under the cumulative ranking curves (SUCRA) values in terms of mortality, intracranial hemorrhage, and adverse event rate among 7 drug therapies in the treatment of cerebral infarction. ( Liu, X; Zhang, JJ, 2018)
"Acute cerebral infarction (ACI) is one of the most commonly seen cerebral vascular disease and the current therapy options are not satisfied."	5.51	Ginkgo leaf extract and dipyridamole injection as adjuvant treatment for acute cerebral infarction: Protocol for systemic review and meta-analysis of randomized controlled trials. ( Liu, Y; Wu, X; Yu, Z, 2019)
"The European/Australasian stroke prevention in reversible ischaemia trial (ESPRIT) confirms that long-term administration of the combination acetylsalicylic acid and dipyridamole is more effective than acetylsalicylic acid in reducing the risk of vascular events after cerebral ischaemia of arterial origin."	5.33	[The combination of acetylsalicylic acid and dipyridamole is more effective in secondary prevention following transient ischaemic attack or cerebral infarction: the debate is closed]. ( De Keyser, JH; Luijckx, GJ, 2006)
"Combination therapy with dipyridamole and aspirin reduces not only the risk of cerebrovascular ischemic events but also the risk of myocardial infarction."	5.07	Antiplatelet therapy is effective in primary prevention of myocardial infarction in patients with a previous cerebrovascular ischemic event. ( Laakso, M; Lowenthal, A; Riekkinen, PJ; Sivenius, J; Smets, P, 1993)
"At the acute phase of cerebral infarction, two recent large studies found that the use of aspirin reduces both mortality and the risk of the recurrence of stroke."	4.80	[Aspirin and cerebral ischemic accidents]. ( Bousser, MG; Crassard, I; Niclot, P, 2000)
"Japanese guidelines recommend aspirin 160-300 mg/day, starting within 48 h, for patients with acute cerebral infarction."	3.80	Enteric-coated aspirin versus other antiplatelet drugs in acute non-cardioembolic ischemic stroke: post-marketing study in Japan. ( Inuyama, L; Mizuno, O; Sakaguchi, T; Takahashi, S; Yamada, T, 2014)
"Co-prescribed aspirin and dipyridamole are more effective than aspirin alone following cerebral infarction; however, patients may struggle with this more complex regimen."	3.78	Persistence, adherence and outcomes with antiplatelet regimens following cerebral infarction in the Tayside Stroke Cohort. ( Doney, AS; Flynn, RW; MacDonald, TM; MacWalter, RS; Murray, GD, 2012)
"Many stroke survivors have severe dysphagia and are unable to take antithrombotic medications orally."	2.75	Pharmacokinetics of extended-release dipyridamole following administration through a gastrostomy tube: an open-label, case-control, two-centre study. ( Batista, LM; Crandell, D; Greer, DM; Lima, FO, 2010)
"The number of fatal and non fatal cerebral infarction was 31 in the P group, 17 in the ASA group, and 18 in the ASA + D group."	2.65	[The A.I.C.L.A. controlled cooperative trial. Secondary prevention of cerebral ischemic accidents due to atherosclerosis by aspirin and dipyridamole. 3: Results]. ( Bousser, MG; Eschwege, E; Haguenau, M; Lefauconnier, JM; Thibult, N; Touboul, D; Touboul, PJ, 1983)
" As for intracranial hemorrhage (ICH), stroke recurrence, and adverse event (AE) rate, there were no significant differences of efficacy among 7 drug therapies."	2.58	Aspirin plus dipyridamole has the highest surface under the cumulative ranking curves (SUCRA) values in terms of mortality, intracranial hemorrhage, and adverse event rate among 7 drug therapies in the treatment of cerebral infarction. ( Liu, X; Zhang, JJ, 2018)
"Acute cerebral infarction (ACI) is one of the most commonly seen cerebral vascular disease and the current therapy options are not satisfied."	1.51	Ginkgo leaf extract and dipyridamole injection as adjuvant treatment for acute cerebral infarction: Protocol for systemic review and meta-analysis of randomized controlled trials. ( Liu, Y; Wu, X; Yu, Z, 2019)
"The dorso-lateral medullary syndrome (Wallenberg's syndrome) is produced by infarction of a wedge of lateral medulla posterior to the inferior olivary nucleus and is usually caused by vertebral artery occlusion."	1.33	The clinical variability of Wallenberg's syndrome. The anatomical correlate of ipsilateral axial lateropulsion. ( Nowak, DA; Topka, HR, 2006)
"The European/Australasian stroke prevention in reversible ischaemia trial (ESPRIT) confirms that long-term administration of the combination acetylsalicylic acid and dipyridamole is more effective than acetylsalicylic acid in reducing the risk of vascular events after cerebral ischaemia of arterial origin."	1.33	[The combination of acetylsalicylic acid and dipyridamole is more effective in secondary prevention following transient ischaemic attack or cerebral infarction: the debate is closed]. ( De Keyser, JH; Luijckx, GJ, 2006)
"Dipyridamole (0."	1.29	Brain SPECT with dipyridamole stress to evaluate cerebral blood flow reserve in carotid artery disease. ( Brannon, WL; Farrell, JJ; Hwang, TL; Saenz, A, 1996)

Research

Studies (42)

Authors

Clinical Trials (2)

Trial Overview

Trial Outcomes

Composite Outcome of Stroke, Myocardial Infarction (MI), or Vascular Death (Antiplatelet Comparison Only)

Timeframe	Studies, this research(%)	All Research%
pre-1990	10 (23.81)	18.7374
1990's	6 (14.29)	18.2507
2000's	19 (45.24)	29.6817
2010's	7 (16.67)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Zhang, JJ	1
Liu, X	1
Liu, Y	1
Wu, X	1
Yu, Z	1
Takahashi, S	1
Mizuno, O	1
Sakaguchi, T	1
Yamada, T	1
Inuyama, L	1
Einecke, D	1
Claes, C	1
Mittendorf, T	1
Grond, M	2
von der Schulenburg, JM	1
Schwab, S	1
Batista, LM	1
Crandell, D	1
Lima, FO	1
Greer, DM	1
Flynn, RW	1
MacDonald, TM	1
Murray, GD	1
MacWalter, RS	1
Doney, AS	1
Weber, R	2
Weimar, C	1
Wanke, I	1
Möller-Hartmann, C	1
Gizewski, ER	1
Blatchford, J	1
Hermansson, K	1
Demchuk, AM	1
Forsting, M	1
Sacco, RL	1
Saver, JL	1
Warach, S	1
Diener, HC	5
Diehl, A	1
Salava, A	1
Alanko, K	1
Hyry, H	1
Uchiyama, S	1
Nowak, DA	1
Topka, HR	1
Schuler, G	1
Luijckx, GJ	1
De Keyser, JH	2
Leys, D	1
Cordonnier, C	1
Schrama, E	1
Eusman, JP	1
Offerhaus, L	1
Aldandashi, S	1
Noor, R	1
Wang, CX	1
Uddin, G	1
Shuaib, A	1
Bousser, MG	3
Eschwege, E	2
Haguenau, M	2
Lefauconnier, JM	2
Thibult, N	2
Touboul, D	2
Touboul, PJ	2
Inoue, T	1
Biller, J	1
Martin, GJ	1
Donaldson, IM	1
Burtsev, EM	1
Usov, LA	1
Atamaniuk, ED	1
Miller, LG	1
Sivenius, J	2
Riekkinen, PJ	2
Lowenthal, A	2
Smets, P	2
Laakso, M	2
Hwang, TL	1
Saenz, A	1
Farrell, JJ	1
Brannon, WL	1
Gorter, JW	1
De Schryver, EL	1
Algra, A	1
Crassard, I	1
Niclot, P	1
Mosso, M	1
Baumgartner, RW	1
Darius, H	1
Bertrand-Hardy, JM	1
Humphreys, M	1
Ostendorf, P	1
Hattori, A	1
Loherstorfer, E	1
Seboldt, H	1
Dichgans, J	1
Matsuda, T	1
Levine, SR	1
Langer, SL	1
Albers, JW	1
Welch, KM	1
Vinichuk, SM	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes: A Double-blind, Active and Placebo Controlled Study of Aggrenox vs. Clopidogrel, With and Without Micardis[NCT00153062]	Phase 4	20,332 participants (Actual)	Interventional	2003-08-31	Completed
Antiplatelet Therapy in Secondary Prevention for Patient With Silent Brain Infarction[NCT03318744]		3,400 participants (Anticipated)	Interventional	2018-01-31	Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Number of patients with any of stroke, myocardial infarction, vascular death (NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years

Composite Outcome of Stroke, Myocardial Infarction, Vascular Death, or New or Worsening Congestive Heart Failure (CHF) (Telmisartan vs. Placebo Only)

Intervention	Participants (Number)
Aspirin + Extended Release Dipyridamole	1333
Clopidogrel	1333

Number of patients with any of stroke, myocardial infarction, vascular death, or new or worsening congestive heart failure (NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years

Number of Patients With First Recurrent Stroke of Any Type, Fatal or Nonfatal (Antiplatelet Comparison Only)

Intervention	Participants (Number)
Telmisartan	1367
Placebo	1463

(NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years

Number of Patients With First Recurrent Stroke of Any Type, Fatal or Nonfatal (Telmisartan vs. Placebo Only)

Intervention	Participants (Number)
Aspirin + Extended Release Dipyridamole	916
Clopidogrel	898